The FDA approved Abiraterone acetate (Zytiga) plus prednisone because it demonstrated a survival benefit for men with metastatic castrate resistant prostate cancer (mCRPC) in the pre-chemotherapy setting.  Given the newness of the approval of Zytiga in this disease stage there is a lack of data on how Zytiga affects the efficacy of enzalutamide (Xtandi) or chemotherapy (docetaxel) when given after Zytiga.

In a study performed at Duke Cancer Institute men who received Zytiga prior to chemotherapy, either on trial or as their treatment, who had also complete follow up on response to subsequent therapy as of the cutoff date, August 12, 2013, were included in this study. The researchers included clinical and demographic information, laboratory values, response, and prog